vs
碧迪（BDX）与Encompass Health Corp（EHC）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Encompass Health Corp的3.4倍（$5.3B vs $1.5B）。Encompass Health Corp净利率更高（9.5% vs 7.3%，领先2.2%）。Encompass Health Corp同比增速更快（9.9% vs -0.4%）。碧迪自由现金流更多（$549.0M vs $116.7M）。过去两年Encompass Health Corp的营收复合增速更高（8.3% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Encompass Health Corp前身为Amcare及HealthSouth，总部位于美国阿拉巴马州伯明翰，是美国规模最大的住院康复服务提供商，在39个州及波多黎各拥有173家住院康复医院，为中风、神经系统疾病、心肺病症、脑损伤等患者提供专业康复诊疗服务。
BDX vs EHC — 直观对比
营收规模更大
BDX
是对方的3.4倍
$1.5B
营收增速更快
EHC
高出10.3%
-0.4%
净利率更高
EHC
高出2.2%
7.3%
自由现金流更多
BDX
多$432.3M
$116.7M
两年增速更快
EHC
近两年复合增速
2.0%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $1.5B |
| 净利润 | $382.0M | $146.1M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 16.7% |
| 净利率 | 7.3% | 9.5% |
| 营收同比 | -0.4% | 9.9% |
| 净利润同比 | 24.0% | 20.8% |
| 每股收益（稀释后） | $1.34 | $1.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXEHC
| Q4 25 | $5.3B | $1.5B | ||
| Q3 25 | $5.9B | $1.5B | ||
| Q2 25 | $5.5B | $1.5B | ||
| Q1 25 | $5.3B | $1.5B | ||
| Q4 24 | $5.2B | $1.4B | ||
| Q3 24 | $5.4B | $1.4B | ||
| Q2 24 | $5.0B | $1.3B | ||
| Q1 24 | $5.0B | $1.3B |
净利润BDXEHC
| Q4 25 | $382.0M | $146.1M | ||
| Q3 25 | $493.0M | $126.5M | ||
| Q2 25 | $574.0M | $142.1M | ||
| Q1 25 | $308.0M | $151.5M | ||
| Q4 24 | $303.0M | $120.9M | ||
| Q3 24 | $400.0M | $108.2M | ||
| Q2 24 | $487.0M | $114.1M | ||
| Q1 24 | $537.0M | $112.5M |
毛利率BDXEHC
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXEHC
| Q4 25 | 10.5% | 16.7% | ||
| Q3 25 | 11.8% | 14.9% | ||
| Q2 25 | 16.0% | 16.2% | ||
| Q1 25 | 10.4% | 16.4% | ||
| Q4 24 | 8.8% | 14.3% | ||
| Q3 24 | 11.4% | 13.6% | ||
| Q2 24 | 12.1% | 14.3% | ||
| Q1 24 | 14.5% | 13.6% |
净利率BDXEHC
| Q4 25 | 7.3% | 9.5% | ||
| Q3 25 | 8.4% | 8.6% | ||
| Q2 25 | 10.4% | 9.7% | ||
| Q1 25 | 5.8% | 10.4% | ||
| Q4 24 | 5.9% | 8.6% | ||
| Q3 24 | 7.4% | 8.0% | ||
| Q2 24 | 9.8% | 8.8% | ||
| Q1 24 | 10.6% | 8.5% |
每股收益（稀释后）BDXEHC
| Q4 25 | $1.34 | $1.43 | ||
| Q3 25 | $1.71 | $1.24 | ||
| Q2 25 | $2.00 | $1.39 | ||
| Q1 25 | $1.07 | $1.48 | ||
| Q4 24 | $1.04 | $1.18 | ||
| Q3 24 | $1.37 | $1.06 | ||
| Q2 24 | $1.68 | $1.12 | ||
| Q1 24 | $1.85 | $1.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $72.2M |
| 总债务越低越好 | — | $2.4B |
| 股东权益账面价值 | $25.3B | $2.4B |
| 总资产 | $54.8B | $7.1B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资BDXEHC
| Q4 25 | $740.0M | $72.2M | ||
| Q3 25 | $641.0M | $48.7M | ||
| Q2 25 | $735.0M | $99.1M | ||
| Q1 25 | $667.0M | $95.8M | ||
| Q4 24 | $711.0M | $85.4M | ||
| Q3 24 | $1.7B | $147.8M | ||
| Q2 24 | $4.5B | $154.4M | ||
| Q1 24 | $2.3B | $134.4M |
总债务BDXEHC
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
股东权益BDXEHC
| Q4 25 | $25.3B | $2.4B | ||
| Q3 25 | $25.4B | $2.4B | ||
| Q2 25 | $25.5B | $2.3B | ||
| Q1 25 | $25.2B | $2.2B | ||
| Q4 24 | $25.2B | $2.1B | ||
| Q3 24 | $25.9B | $2.0B | ||
| Q2 24 | $25.9B | $1.8B | ||
| Q1 24 | $25.6B | $1.7B |
总资产BDXEHC
| Q4 25 | $54.8B | $7.1B | ||
| Q3 25 | $55.3B | $6.9B | ||
| Q2 25 | $54.9B | $6.8B | ||
| Q1 25 | $54.5B | $6.6B | ||
| Q4 24 | $54.7B | $6.5B | ||
| Q3 24 | $57.3B | $6.5B | ||
| Q2 24 | $55.6B | $6.4B | ||
| Q1 24 | $54.2B | $6.2B |
负债/权益比BDXEHC
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.46× | ||
| Q1 24 | — | 1.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $346.0M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $116.7M |
| 自由现金流率自由现金流/营收 | 10.5% | 7.6% |
| 资本支出强度资本支出/营收 | 2.1% | 14.8% |
| 现金转化率经营现金流/净利润 | 1.72× | 2.37× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $439.2M |
8季度趋势，按日历期对齐
经营现金流BDXEHC
| Q4 25 | $657.0M | $346.0M | ||
| Q3 25 | $1.4B | $270.8M | ||
| Q2 25 | $1.2B | $270.2M | ||
| Q1 25 | $164.0M | $288.6M | ||
| Q4 24 | $693.0M | $278.8M | ||
| Q3 24 | $1.2B | $267.8M | ||
| Q2 24 | $1.3B | $217.4M | ||
| Q1 24 | $514.0M | $238.8M |
自由现金流BDXEHC
| Q4 25 | $549.0M | $116.7M | ||
| Q3 25 | $1.0B | $83.7M | ||
| Q2 25 | $1.0B | $113.3M | ||
| Q1 25 | $35.0M | $125.5M | ||
| Q4 24 | $588.0M | $80.1M | ||
| Q3 24 | $882.0M | $120.3M | ||
| Q2 24 | $1.1B | $60.5M | ||
| Q1 24 | $380.0M | $99.4M |
自由现金流率BDXEHC
| Q4 25 | 10.5% | 7.6% | ||
| Q3 25 | 17.0% | 5.7% | ||
| Q2 25 | 19.0% | 7.8% | ||
| Q1 25 | 0.7% | 8.6% | ||
| Q4 24 | 11.4% | 5.7% | ||
| Q3 24 | 16.2% | 8.9% | ||
| Q2 24 | 22.4% | 4.6% | ||
| Q1 24 | 7.5% | 7.6% |
资本支出强度BDXEHC
| Q4 25 | 2.1% | 14.8% | ||
| Q3 25 | 6.0% | 12.7% | ||
| Q2 25 | 3.2% | 10.8% | ||
| Q1 25 | 2.4% | 11.2% | ||
| Q4 24 | 2.0% | 14.1% | ||
| Q3 24 | 5.4% | 10.9% | ||
| Q2 24 | 3.6% | 12.1% | ||
| Q1 24 | 2.7% | 10.6% |
现金转化率BDXEHC
| Q4 25 | 1.72× | 2.37× | ||
| Q3 25 | 2.75× | 2.14× | ||
| Q2 25 | 2.12× | 1.90× | ||
| Q1 25 | 0.53× | 1.90× | ||
| Q4 24 | 2.29× | 2.31× | ||
| Q3 24 | 2.94× | 2.48× | ||
| Q2 24 | 2.66× | 1.91× | ||
| Q1 24 | 0.96× | 2.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
